La cadena de opciones muestra datos clave de las opciones de acciones de Vaccinex a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Vaccinex..

Vaccinex (OTC:VCNX) Bolsa, Cadena de Opciones

Vaccinex

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

Vaccinex Inc

Truist Securities analyst Gregory Miller maintains RLJ Lodging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLJ#NYSE">RLJ</a>) with a Hold and lowers the price target from $10 to $7.

News

Price Target

Analyst Ratings

Truist Securities Maintains Hold on RLJ Lodging, Lowers Price Target to $7

Company opens new engineering center of excellence in the UK and an aerostructures production line in France
PARIS, June 9, 2025 /PRNewswire/ -- Collins Aerospace, an&nbsp;RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) business, expanded its aircraft electrification capabilities with the introduction of a new engineering center of excellence in Wolverhampton, UK, and a new electric thrust reverser actuation systems (elecTRAS&#x2122;) production line in Colomiers, France. The Wolverhampton center focuses on developing next-generation electric thrust reverser actuation systems for commercial aircraft, featuring state-of-the-art design and test capabilities, and the Colomiers facility will handle the final assembly of these advanced electric systems, enhancing production efficiency and capacity.
By switching from traditional hydraulic-powered thrust reverser actuation systems to elecTRAS, Collins can design nacelle systems that are easier for customers to install and maintain, while also reducing aircraft system weight by 15-20%. This improves fuel efficiency and operational performance. Collins currently supplies the elecTRAS on the Airbus A350 family. As part of an aircraft's nacelle system, thrust reversers redirect thrust from the plane's engines to help it slow down upon landing.&nbsp;
The final assembly of the system in Colomiers will increase Collins' nacelle integration capacity and enhance customer proximity. Collectively, these efforts will strengthen Collins' aircraft electrification capabilities to support its global customer base.

Global

RTX's Collins Aerospace Expands Aircraft Electrification With New UK Engineering Center And French Production Line For Electric Thrust Reverser Actuation Systems

Wall Street opens the week on a quiet note, with major indexes steady as investors await potential trade breakthroughs during high-level <a href="https://www.benzinga.com/news/econ-s">U.S.-China talks in London.</a>
The S&amp;P 500 is flat at 6,000, holding near record highs after rallying nearly 25% since the April 7 low, while the Nasdaq 100 inched 0.3% higher to 21,830.
Small-cap stocks continue to outperform, extending their catch-up trade, with the Russell 2000 up 0.7% to its highest level since early March.
The lack of market-moving economic data kept the U.S. dollar and Treasury yields little changed. The 10-year yield holds around 4.47%, while the 30-year sits at 4.96%.
Gold resumed its upward trend, gaining 0.8% to $3,330 per ounce after two days of declines. But it&#8217;s silver that continues to steal the spotlight, surging nearly 2% to $36.67 per ounce — the highest level since February 2012 — and up more than 10% over the past week, as investors seek the next bullish trade in metals following gold's 2025 breakout.
Other metals also rallied, with platinum up 4%, palladium rising 3.1% and copper gaining 2%.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) attracted fresh bids, climbing above $108,000 to its highest level since May 29.
<h1 class="wp-block-heading">Monday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg %</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,145.65</td>
<td>0.7%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,826.91</td>
<td>0.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,009.21</td>
<td>0.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,761.90</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:35 p.m. ET </figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched up by 0.2% to $600.02.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) flattened at $428.36.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.3% to $531.33.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.7% to $213.34.</li>
<li>The&nbsp;Materials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) outperformed, up 0.9%; the&nbsp;Financials&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) lagged, down 0.7%.</li>
</ul>
<h1 class="wp-block-heading">Monday&#8217;s Stock Movers</h1>
<ul class="wp-block-list">
<li>Cameco Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>) rallied by 11%, reaching new all-time highs after a slew of investment banks, including Scotiabank and BMO Capital, raised the price target.</li>
<li>Mining giant Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) rose 2.8%, hitting levels last seen in late March. </li>
<li>Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) rallied over 5% after Bank of America raised the price target from $135 to $150. </li>
<li>Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>), Joby Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) and Vertical Aerospace Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) each gained around 15% after a White House executive order on Friday directed federal agencies to expand drone and electric aircraft operations in U.S. airspace. Read Next: • <a href="https://www.benzinga.com/trading-ideas/technicals/25/06/45841945/stock-of-the-day-nvidia-tests-new-resistance-could-another-breakout-be-brewing">Stock Of The Day: NVIDIA Tests New Resistance — Could Another Breakout Be Brewing?</a> Photo: Shutterstock </li>
</ul>

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Macro Economic Events

Mid Cap

Broad U.S. Equity ETFs

Specialty ETFs

Commodities

Small Cap

Economics

Tech

ETFs

$BTC

ACHR

SPDR Dow Jones Industrial Average ETF Trust

EVTL

JOBY

Select Sector SPDR-Consumer Discretionary

Silver Breaks Past 13-Year Highs, Small Caps Rise, Bitcoin Tops $108,000: What's Driving Markets Monday?

Truist Securities analyst Gregory Miller maintains OneSpaWorld Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSW#NASDAQ">OSW</a>) with a Buy and raises the price target from $19 to $21.

Truist Securities Maintains Buy on OneSpaWorld Hldgs, Raises Price Target to $21

<a href="https://www.bloomberg.com/news/articles/2025-06-09/gfl-is-said-to-consider-sale-of-stake-in-c-5-billion-infra-arm" title="https://www.bloomberg.com/news/articles/2025-06-09/gfl-is-said-to-consider-sale-of-stake-in-c-5-billion-infra-arm">https://www.bloomberg.com/news/articles/2025-06-09/gfl-is-said-to-consider-sale-of-stake-in-c-5-billion-infra-arm</a>

Asset Sales

'GFL Is Said to Consider Sale of Stake in C$5 Billion Infra Arm' - Bloomberg News

Truist Securities analyst Michael Lewis maintains National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) with a Hold and raises the price target from $76 to $77.

Truist Securities Maintains Hold on National Health Investors, Raises Price Target to $77

Truist Securities analyst Michael Lewis maintains American Healthcare REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHR#NYSE">AHR</a>) with a Buy and raises the price target from $32 to $38.

Truist Securities Maintains Buy on American Healthcare REIT, Raises Price Target to $38

Trading Ideas

Ohmyhome Shares Halted On Circuit Breaker To The Upside, Stock Now Up 204.9%

<a href="https://www.apple.com/apple-events/event-stream/?useASL=true" title="https://www.apple.com/apple-events/event-stream/?useASL=true">https://www.apple.com/apple-events/event-stream/?useASL=true</a>

Events

AAPL

Apple Highlights New Genmogi, Generative AI Features For Texting

Truist Securities analyst David Macdonald maintains Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) with a Buy and lowers the price target from $510 to $500.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Truist Securities Maintains Buy on Elevance Health, Lowers Price Target to $500

<a href="https://register.epo.org/application?number=EP21788894" title="https://register.epo.org/application?number=EP21788894">https://register.epo.org/application?number=EP21788894</a>

Biotech

General

AEMD

Aethlon Medical Has Been Granted European Patent Number EP4136453 Titled "LECTIN FOR USE IN METHODS FOR TREATING A SEQUELA OF CORONAVIRUS INFECTION"

Truist Securities analyst Ki Bin Kim maintains Macerich (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAC#NYSE">MAC</a>) with a Buy and raises the price target from $19 to $21.

Truist Securities Maintains Buy on Macerich, Raises Price Target to $21

Apple Highlights New Calling Features In iOS 26, With 'Hold Assist'

Raymond James analyst Bobby Griffin initiates coverage on Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) with a Market Perform rating.

Initiation

ARHS

Raymond James Initiates Coverage On Arhaus with Market Perform Rating

Barclays analyst Brian Morton maintains Toronto-Dominion Bank (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TD#TSX">TD</a>) with a Underweight and raises the price target from C$83 to C$91.

TSX:TD

Barclays Maintains Underweight on Toronto-Dominion Bank, Raises Price Target to C$91

Piper Sandler analyst Jessica Tassan maintains Oscar Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) with a Overweight and lowers the price target from $25 to $18.

OSCR

Piper Sandler Maintains Overweight on Oscar Health, Lowers Price Target to $18

<a href="https://www.reuters.com/business/healthcare-pharmaceuticals/unitedhealth-eyes-1-billion-deal-exit-latin-america-insurer-refocuses-us-sources-2025-06-09/#:~:text=UnitedHealth%20left%20Brazil%20in%202023,proposals%20as%20soon%20as%20July" title="https://www.reuters.com/business/healthcare-pharmaceuticals/unitedhealth-eyes-1-billion-deal-exit-latin-america-insurer-refocuses-us-sources-2025-06-09/#:~:text=UnitedHealth%20left%20Brazil%20in%202023,proposals%20as%20soon%20as%20July">https://www.reuters.com/business/healthcare-pharmaceuticals/unitedhealth-eyes-1-billion-deal-exit-latin-america-insurer-refocuses-us-sources-2025-06-09/#:~:text=UnitedHealth%20left%20Brazil%20in%202023,proposals%20as%20soon%20as%20July</a>.

Reported Earlier: 'UnitedHealth Eyes $1 Billion Deal To Exit Latin America As Insurer Refocuses On US, Sources Say' - Reuters News

Piper Sandler analyst Mark Lear initiates coverage on Crescent Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRGY#NYSE">CRGY</a>) with a Overweight rating and announces Price Target of $14.

CRGY

Piper Sandler Initiates Coverage On Crescent Energy with Overweight Rating, Announces Price Target of $14

Apple Highlights iOS 26 CarPlay Features

Apple Highlights Redesigned Facetime Page

Financing

Press Releases

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

Health Care

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference on October 31, 2024

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting

Vaccinex Provides Update on ActivMAb® Platform:  Multiple Project Deals and Presentation at SITC

Earnings

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

Markets

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

Comments

Vaccinex

Vaccinex (VCNX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL